Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure.

Heart (British Cardiac Society)·2021

Same author

Cardiovascular professional societies fall short in providing impartial, clear and evidence-based guidelines.

Heart (British Cardiac Society)·2021

Same author

Coronary Computed Tomography Angiography to Triage Patients With Non-ST-Segment Elevation Acute Coronary Syndrome.

Journal of the American College of Cardiology·2021

Same author

<i>CARMN</i> Loss Regulates Smooth Muscle Cells and Accelerates Atherosclerosis in Mice.

Circulation research·2021

Same author

MINOCA: a heterogenous group of conditions associated with myocardial damage.

Heart (British Cardiac Society)·2021

Same author

Comparison of Correction Techniques for the Spill in Effect in Emission Tomography.

IEEE transactions on radiation and plasma medical sciences·2021

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Urocortins in heart failure.

Sowmya Venkatasubramanian¹, David E Newby, Ninian N Lang

¹Centre for Cardiovascular Science, University of Edinburgh, SU. 305, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, United Kingdom. s.venkat@ed.ac.uk

Biochemical Pharmacology

|April 6, 2010

Summary

Urocortins, peptides acting via corticotropin-releasing hormone (CRH) receptors, show promise for treating heart failure. Their beneficial cardiovascular effects, including vasodilation and improved heart function, are increasingly recognized in disease states.

Related Experiment Videos

Last Updated: Jun 14, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Area of Science:

Cardiovascular Physiology
Endocrinology
Molecular Medicine

Background:

Heart disease and heart failure are leading causes of mortality.
Novel peptides are emerging as potential biomarkers and therapeutics for cardiovascular conditions.
Urocortins are a class of peptides with increasingly recognized roles in cardiovascular health and disease.

Purpose of the Study:

To review the role of urocortins in normal cardiovascular physiology.
To examine the involvement of urocortins in the pathophysiology of heart failure.
To highlight urocortins as potential therapeutic targets for heart failure.

Main Methods:

Review of existing scientific literature on urocortins and cardiovascular function.
Analysis of studies investigating urocortin signaling pathways (corticotropin-releasing hormone receptors).
Examination of experimental and clinical data on urocortin activity in heart failure models.

Main Results:

Urocortins exert cardiovascular effects through corticotropin-releasing hormone (CRH) receptors and intracellular signaling.
Urocortins demonstrate favorable hemodynamic and neurohumoral regulatory effects.
Observed vascular relaxation and positive inotropic, chronotropic, and lusitropic effects on the heart.

Conclusions:

Urocortins possess properties that make them attractive therapeutic targets for heart failure.
Increased urocortin activity is noted in experimental and clinical heart failure, with augmented responses.
Further research into urocortins may lead to novel treatments for cardiovascular diseases.